Remove 2023 Remove Compounding Remove Vaccines
article thumbnail

The Pandemic Treaty and the opportunity to end ‘vaccine apartheid’

pharmaphorum

Ben Hargreaves discovers why some have referred to the distribution of COVID-19 vaccines and treatments as a form of apartheid. Vaccine access for a price. Tendayi Achium, labelled the response by the global community as a form of “vaccine apartheid,” a suggestion echoed by the organisation’s director general.

article thumbnail

Top 5 Reasons to Attend the 2023 ISPE Aseptic Conference

ISPE

Top 5 Reasons to Attend the 2023 ISPE Aseptic Conference. Top 5 Reasons to Attend the 2023 ISPE Aseptic Conference. I presented on planning and executing and designing fill lines, RABS, Isolators, and transfers – along with the differences between processing potent compounds versus non- potent compounds. Trudy Patterson.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nine for 2023, part two: healthcare’s hard problem, the prognosis for diagnosis, and key new pharmacotherapy platforms

pharmaphorum

The present article focuses on opportunity, the unmet need which lies at the heart of better healthcare provision, and two areas of growth and opportunity: Point of Care Diagnostics, and the new pharmacotherapy classes which will commercialise for the first time in 2023. Innovation will power the market.

FDA 98
article thumbnail

STAT+: Pharmalittle: We’re reading about doctors powering telehealth GLP-1 scripts, an FDA hold on a Novavax shot, and more

STAT

… Just a handful of networks of doctors, nurse practitioners, and physician assistants are writing prescriptions for dozens of websites offering the GLP-1 weight loss drugs, including the compounded versions that have been the subject of conflict and debate among clinicians and industry members , STAT reports.

FDA 90
article thumbnail

Injectable drug delivery market to value $1139.4b by 2029

European Pharmaceutical Review

percent compound annual growth rate (CAGR) between 2024 to 2029. Injectable vaccines activate the immune system to help to prevent infectious conditions such as influenza. A new report by MarketsandMarkets has predicted that the injectable drug delivery market will reach an 8.6 The market is anticipated to value $1139.4

article thumbnail

Global cell line development to surge in next decade

European Pharmaceutical Review

million in 2023, with a predicted compound annual growth rate (CAGR) of 4.1 Demand for cell lines “in drug development , vaccine production, and therapeutic research is surging”, setting the market up for significant expansion, Ghosh noted. Total cell line product sales are expected to reach $3,124.4

article thumbnail

Microbial fermentation tech market to exceed $56.9b by 2033

European Pharmaceutical Review

Therefore, the projected compound annual growth rate (CAGR) is 5.7 million in 2023. The key drivers of this industry include advancements in bioprocessing, development of novel microbial strains for production of high-value compounds and the rising demand for biopharmaceutical products such as antibiotics, vaccines and enzymes.